Pieris CMO Tim Demuth steps down effective Sept 30, 2022; severance of €265,125

PALVELLA THERAPEUTICS, INC.

Tim Demuth, M.D., Ph.D., Senior VP and CMO, mutually agreed to depart Pieris; effective September 30, 2022.
Separation agreement includes 2 months base salary continuation and retirement contributions through Separation Date.
Dr. Demuth will receive a pro-rata 2022 discretionary bonus and severance of €265,125 (~$270,427).
Payments subject to release of claims and ongoing confidentiality obligations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tim Demuth

Senior Vice President and Chief Medical Officer

PVLA · PALVELLA THERAPEUTICS, INC.

Effective: 2022-09-30
Filed: August 4, 2022, 7:59 PM ET

On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the " Company ") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim Demuth departed as Senior Vice President and Chief Medical Officer at PALVELLA THERAPEUTICS, INC..

Action: stepped down
Role: Senior Vice President and Chief Medical Officer

Exact text from the filing

On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the " Company ") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 ("Separation Date").

View on SEC.gov

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001583648-22-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.